MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Kite Pharma, Inc. (Details) $ / shares in Units, $ in Thousands	1 Months Ended
	Mar. 31, 2023 USD ($) $ / shares	Sep. 30, 2019 USD ($) performance_obligation material_right	Apr. 30, 2018 USD ($) milestone option	Dec. 31, 2022 USD ($)
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Accounts receivable	$ 7,026			$ 3,678
Kite Pharma, Inc.
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Change in estimate of transaction price, increase in revenue	8,900
Increased net income	$ 8,900
Increased earnings per share, basic (in dollars per share) | $ / shares	$ 0.06
Increased earnings per share, diluted (in dollars per share) | $ / shares	$ 0.05
Kite Pharma, Inc. | License and Service
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contract with customer liability			$ 150,000
Number of remaining performance obligations | performance_obligation		4
Number of material rights for renewal of research period | material_right		2
Renewal period		1 year
Fixed consideration		$ 150,000
Remaining performance obligation amount	$ 8,600			21,200
Remaining performance obligation amount, related to material rights	1,500			1,500
Kite Pharma, Inc. | Collaboration And License Agreement
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Milestone payments received			$ 150,000
Initial research term of agreement			6 years
Number of options to extend initial research term | option			2
Extended research term of agreement			1 year
Separate fee for additional term			$ 10,000
Contract with customer liability	8,000			19,400
Accounts receivable	$ 1,000			$ 700
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified research, clinical development, regulatory and first commercial sale milestones
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development and sales-based milestone payments to be received			1,300,000
Kite Pharma, Inc. | Collaboration And License Agreement | Achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Contingent development and sales-based milestone payments to be received			$ 1,800,000
Maximum amount of achieved milestones to receive payment | milestone			10
Kite Pharma, Inc. | Collaboration And License Agreement | Maximum
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Development and sales-based milestone payments to be received			$ 3,000,000